NASDAQ Composite opens in less than ten hours and Arena Pharmaceuticals’s premarket value is already 1.67% down.
The last session, NASDAQ Composite finished with Arena Pharmaceuticals rising 1.71% to $78.31. NASDAQ Composite rose 0.43% to $13,128.95, after two consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session.
Arena Pharmaceuticals’s last close was $78.31, 15.17% under its 52-week high of $90.19.
Arena Pharmaceuticals’s Sales
Arena Pharmaceuticals’s sales growth is a negative 81.3% for the ongoing quarter and 155.7% for the next. The company’s growth estimates for the present quarter is a negative 4.5% and positive 4.5% for the next.
Arena Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth declined by 98.5%, now sitting on 3.28M for the twelve trailing months.
Arena Pharmaceuticals’s Stock Yearly Top and Bottom Value
Arena Pharmaceuticals’s stock is valued at $78.31 at 23:36 EST, way below its 52-week high of $90.19 and way higher than its 52-week low of $32.95.
Arena Pharmaceuticals’s Moving Average
Arena Pharmaceuticals’s worth is above its 50-day moving average of $71.98 and way above its 200-day moving average of $70.97.
Volatility
Arena Pharmaceuticals’s last day, last week, and last month’s average volatility was 1.71%, 0.48%, and 0.59%, respectively.
Arena Pharmaceuticals’s last day, last week, and last month’s high and low average amplitude percentage was 7.15%, 4.71%, and 3.72%, respectively.
